Update in Infectious Diseases
Authors: John G. Bartlett
Journal: Annals of Internal Medicine (1999)

Updates from the Annual Session17 August 1999Update in Infectious DiseasesJohn G. Bartlett, MDJohn G. Bartlett, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-4-199908170-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail An uninterrupted flow of new information and new concepts makes infectious diseases one of the fastest-changing fields of clinical medicine. The emergence of antibiotic-resistant organisms, notably gram-positive cocci, continues unabated. Food-borne disease is also a continuing problem. Among the major culprits are Listeria species, Escherichia coli O157, and Salmonella species, and Cyclospora species have made a dramatic return. The role of irradiation in preventing food-borne illness has been discussed, as have the vital issues posed by bioterrorism. A most exciting prospect is the potential role that certain treatable bacterial infections may play in coronary heart disease and resultant acute myocardial ...References1. Gonzales R, Steiner JF, Lum A, Barrett PH. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999;281:1512-9. CrossrefMedlineGoogle Scholar2. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, et al . Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med. 1999;340:1525-32. CrossrefMedlineGoogle Scholar3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [Letter]. J Antimicrob Chemother. 1997;40:135-6. CrossrefMedlineGoogle Scholar4. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999;340:517-23. CrossrefMedlineGoogle Scholar5. Waldvogel FA. New resistance in Staphylococcus aureus [Editorial]. N Engl J Med. 1999;340:556-7. CrossrefMedlineGoogle Scholar6. Durack DT. Antibiotics for prevention of endocarditis during dentistry: time to scale back? Ann Intern Med. 1998;129:829-31. LinkGoogle Scholar7. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al . Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-71. CrossrefMedlineGoogle Scholar8. Folsom AR. Antibiotics for prevention of myocardial infarction? Not yet! [Editorial]. JAMA. 1999;281:461-2. CrossrefMedlineGoogle Scholar9. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al . Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997;337:874-80. CrossrefMedlineGoogle Scholar10. Herwaldt BL, Ackers M. An outbreak in 1996 of cyclosporiasis associated with imported raspberries. The Cyclospora Working Group. N Engl J Med. 1997;336:1548-56. CrossrefMedlineGoogle Scholar11. Osterholm MT. Lessons learned again: cyclosporiasis and raspberries [Editorial]. Ann Intern Med. 1999;130:233-4. LinkGoogle Scholar12. Henderson DA. The looming threat of bioterrorism. Science. 1999;283:1279-82. CrossrefMedlineGoogle Scholar13. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al . Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353:863-8. CrossrefMedlineGoogle Scholar14. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al . The care of HIV-infected adults in U.S. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897-904. CrossrefMedlineGoogle Scholar15. . Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet. 1999;353:1035-9. CrossrefMedlineGoogle Scholar16. Stringer JS, Rouse DJ, Goldberg RL. Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint. JAMA. 1999;281:1946-9. CrossrefMedlineGoogle Scholar17. Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis. 1999;28:14-22. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Corresponding Author: John G. Bartlett, MD, 1830 Monument Street, Room 437, Baltimore, MD 21205. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPreparedness for BioterrorismBioterrorism and Bioterrorism Preparedness: Historical Perspective and OverviewUpdate in Internal MedicineInfluenza: New insights into an old disease 17 August 1999Volume 131, Issue 4Page: 273-280KeywordsAntibioticsCyclosporaDrugsFoodHIVHIV infectionsInfectious diseasesPenicillinPneumoniaVancomycin ePublished: 15 August 2000 Issue Published: 17 August 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...